Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Single-arm, Open-label, Multicenter Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in 2 Parallel Cohorts of Premenopausal Women With Early-stage and Advanced Hormone Receptor-positive (HR+) Breast Cancer

NCT07310420 is registered in ClinicalTrials.gov with TerSera Therapeutics LLC as lead sponsor.

NCT NCT07310420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07310420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Single-arm, Open-label, Multicenter Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in 2 Parallel Cohorts of Premenopausal Women With Early-stage and Advanced Hormone Receptor-positive (HR+) Breast Cancer
Lead sponsor
TerSera Therapeutics LLC
Phase
Phase 1
Overall status
Recruiting
Start date
October 30, 2026
Completion date
July 31, 2027
Enrollment
176 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, early breast cancer